Sensydia Welcomes Brit Gould as Chief Commercial Officer to Propel Cardiac Performance System Launch

Sensydia's New Leadership in Cardiac Technology

Sensydia, a pioneering medical technology firm focused on non-invasive cardiac monitoring, recently announced the appointment of Brit Gould as its Chief Commercial Officer (CCO). This strategic move is aimed at advancing the commercialization of the Cardiac Performance System (CPS™), an innovative platform designed to improve how clinicians assess hemodynamic function.

Since 2024, Brit Gould has been critically involved with Sensydia, previously serving as Vice President of Marketing and Market Access. His consistent efforts in guiding the company’s market strategy have made a significant impact, laying a strong foundation for the CPS’s launch. Under his leadership, Sensydia has effectively engaged with clinicians to better understand their needs and gathered essential feedback that has shaped product development.

In his new role, Gould will oversee commercial strategy, reimbursement processes, and the development of the commercial organization necessary for a successful market entry of CPS. As the company gears up for its ACOUSTIC-1 study, which is crucial for the product’s commercial launch, Gould's extensive experience in the medical device industry is expected to play a decisive role.

Gould's background is impressive, with over 20 years in commercial leadership roles across medical devices and diagnostics, including pioneering AI-driven cardiac diagnostics. Previously, at iRhythm Technologies, he was instrumental in launching Zio AT, the company's first mobile cardiac telemetry solution. Moreover, his tenure as Vice President of Marketing at Eko Health and leading a new platform launch at Boston Scientific further showcases his capability.

Notably, Gould holds both a bachelor’s and master’s degree in Electrical Engineering and Computer Science from MIT, along with an MBA from the Kellogg School of Management at Northwestern University. His proficiency is not just academic; he is also a named inventor on 13 patents.

In a statement about his new role, Gould expressed his vision for the Cardiac Performance System, highlighting, "Heart failure is managed day to day in the office and clinic, yet the most definitive pressure information still comes from the catheterization lab. CPS is designed to close that gap." His focus is to ensure that CPS reaches clinicians and their patients promptly, enhancing the future of cardiac care.

The Cardiac Performance System is designed to enable rapid, safe, and accurate assessments of cardiac function without invasive procedures, aiming to empower doctors in the early identification and management of heart failure and pulmonary hypertension. It recently received the FDA's Breakthrough Device designation, underscoring its potential to significantly advance patient outcomes. Sensydia's previous achievements in regulatory success include receiving FDA 510(k) clearance in 2018, which recognized their algorithm for non-invasive measurement of ejection fraction.

Company CEO Anthony Arnold remarked on Gould's appointment, stating, "Brit has been shaping Sensydia's path to market for two years, from understanding clinicians' needs to establishing the coding foundation for reimbursement of non-invasive hemodynamic assessment." Arnold's enthusiasm for Gould's transition into the role reflects confidence in his ability to leverage his considerable expertise in ensuring a successful launch.

In conclusion, Brit Gould stepping into the Chief Commercial Officer position at Sensydia marks a pivotal moment for the company as it prepares for the launch of its groundbreaking Cardiac Performance System. With his leadership and the dedication of the Sensydia team, the future of non-invasive cardiac assessment looks promising, paving the way for improved patient care and outcomes. As the project progresses, stakeholders will be keenly watching how these developments unfold, setting new standards for the medical technology landscape.